Sign in
CompletedNo phase

Long-term Follow-up of Phase 1 Clinical Trial of CS10BR05(CS10BR05-MSA101)

Key facts

Who runs it
Corestemchemon, Inc.
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
8 people enrolled
Started
28 Aug 2018
Ended
25 Sept 2024
Type of study
Observational
Record updated
7 January 2025

Who can take part

Sex
Women and men

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Subjects who participated in the phase 1 clinical trial(Protocol No.: CS10BR05- MSA101) at 3 months after administering investigational product
  • Subjects who give a written, signed and dated informed consent spontaneously

Who cannot take part

  • Subjects who decided as inappropriate cases to participate in the observational study by investigator

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The study purpose is conducting follow-up surveillance for the incidence of adverse events and efficacy of subjects participated in phase 1 trial to evaluate the safety and tolerability of autologous bone marrow-derived mesenchymal stem cells (CS10BR05) in subjects with Multiple System Atrophy until 60 months from administering investigational product (IP).

The group in the trial

  • Non-Interventional Study group

    Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Observational Study of Long-term Safety and Efficacy of Subjects Who Participated in CS10BR05 Inj. Phase 1 Study
Record updated
7 January 2025